The AMA report reveals high market concentration among pharmacy benefit managers (PBMs), vertical integration with insurers, and calls for increased transparency and regulatory reforms to control drug prices and enhance competition.

Moody's report highlights impending Medicaid cuts, insurer financial pressures, evolving Medicare Advantage rates, and trends in U.S. healthcare leadership and technology.

Analysis shows a 25% increase in U.S. private insurer prescription drug denials from 2016-2023, driven by rising drug costs and claim automation. Insights into industry impact and reform efforts.